{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699994495416960.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1038/leu.2009.147"}},{"identifier":{"@type":"URI","@value":"https://www.nature.com/articles/leu2009147.pdf"}},{"identifier":{"@type":"URI","@value":"https://www.nature.com/articles/leu2009147"}}],"dc:title":[{"@value":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380004231519907206","@type":"Researcher","foaf:name":[{"@value":"M A Dimopoulos"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994495416965","@type":"Researcher","foaf:name":[{"@value":"C Chen"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994495417090","@type":"Researcher","foaf:name":[{"@value":"A Spencer"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994495416963","@type":"Researcher","foaf:name":[{"@value":"R Niesvizky"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994495416960","@type":"Researcher","foaf:name":[{"@value":"M Attal"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994495417088","@type":"Researcher","foaf:name":[{"@value":"E A Stadtmauer"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994495417093","@type":"Researcher","foaf:name":[{"@value":"M T Petrucci"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994495417091","@type":"Researcher","foaf:name":[{"@value":"Z Yu"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994495417092","@type":"Researcher","foaf:name":[{"@value":"M Olesnyckyj"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994495416964","@type":"Researcher","foaf:name":[{"@value":"J B Zeldis"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994495416962","@type":"Researcher","foaf:name":[{"@value":"R D Knight"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994495417089","@type":"Researcher","foaf:name":[{"@value":"D M Weber"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"08876924"},{"@type":"EISSN","@value":"14765551"}],"prism:publicationName":[{"@value":"Leukemia"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2009-07-23","prism:volume":"23","prism:number":"11","prism:startingPage":"2147","prism:endingPage":"2152"},"reviewed":"false","dc:rights":["https://www.springer.com/tdm","https://www.springer.com/tdm"],"url":[{"@id":"https://www.nature.com/articles/leu2009147.pdf"},{"@id":"https://www.nature.com/articles/leu2009147"}],"createdAt":"2009-07-23","modifiedAt":"2022-03-31","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004231519907200","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004231521222912","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical significance of cancer-related fatigue in multiple myeloma patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360005516137374592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142851569024","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617498876800","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181473692928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181955712512","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A novel derivative (GTN024) from a natural product, komaroviquinone, induced the apoptosis of high-risk myeloma cells via reactive oxygen production and ER stress"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567187490743936","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360572092876926720","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Changing trend in mortality rate of multiple myeloma after introduction of novel agents: A population‐based study"},{"@language":"en","@value":"Changing trend in mortality rate of multiple myeloma after introduction of novel agents: A population-based study."}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205421683456","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Autologous stem cell transplantation for multiple myeloma"},{"@language":"ja","@value":"多発性骨髄腫に対する自家造血幹細胞移植"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206445432960","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Molecular Targeting Therapies for Multiple Myeloma."},{"@language":"ja","@value":"多発性骨髄腫に対する分子標的療法"},{"@value":"医学と医療の最前線 多発性骨髄腫に対する分子標的療法"},{"@language":"ja-Kana","@value":"イガク ト イリョウ ノ サイゼンセン タハツセイ コツズイシュ ニ タイスル ブンシ ヒョウテキ リョウホウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390845713029559168","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1038/leu.2009.147"},{"@type":"CROSSREF","@value":"10.1007/s12185-013-1321-0_references_DOI_YJmO0OUEylBkEw1hiPpAByklmMp"},{"@type":"CROSSREF","@value":"10.1007/s12185-018-2516-1_references_DOI_YJmO0OUEylBkEw1hiPpAByklmMp"},{"@type":"CROSSREF","@value":"10.1007/s12185-019-02669-z_references_DOI_YJmO0OUEylBkEw1hiPpAByklmMp"},{"@type":"CROSSREF","@value":"10.1182/bloodadvances.2019001410_references_DOI_YJmO0OUEylBkEw1hiPpAByklmMp"},{"@type":"CROSSREF","@value":"10.1002/hon.2863_references_DOI_YJmO0OUEylBkEw1hiPpAByklmMp"},{"@type":"CROSSREF","@value":"10.1007/s12185-014-1696-6_references_DOI_YJmO0OUEylBkEw1hiPpAByklmMp"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0083905_references_DOI_YJmO0OUEylBkEw1hiPpAByklmMp"},{"@type":"CROSSREF","@value":"10.2169/naika.99.142_references_DOI_YJmO0OUEylBkEw1hiPpAByklmMp"},{"@type":"CROSSREF","@value":"10.1002/ijc.33135_references_DOI_YJmO0OUEylBkEw1hiPpAByklmMp"},{"@type":"CROSSREF","@value":"10.7889/hct.3.64_references_DOI_YJmO0OUEylBkEw1hiPpAByklmMp"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.1018-18_references_DOI_YJmO0OUEylBkEw1hiPpAByklmMp"},{"@type":"CROSSREF","@value":"10.1016/j.bbrc.2018.09.177_references_DOI_YJmO0OUEylBkEw1hiPpAByklmMp"}]}